Publications
Found 6 results
Filters: Author is C.J. Tang [Clear All Filters]
, “Clinical significance of SHMT1 rs1979277 polymorphism in Asian solid tumors: evidence from a meta-analysis”, vol. 14, pp. 5602-5614, 2015.
, “Implicating the H63D polymorphism in the HFE gene in increased incidence of solid cancers: a meta-analysis”, vol. 14, pp. 13735-13745, 2015.
, “Meta-analysis of epidemiological studies of association of two polymorphisms in the interleukin-10 gene promoter and colorectal cancer risk”, vol. 11, pp. 3389-3397, 2012.
Baniyash M (2006). Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin. Cancer Biol. 16: 80-88.
http://dx.doi.org/10.1016/j.semcancer.2005.12.002
PMid:16420981
Breslow NE and Day NE (1987). Statistical methods in cancer research. Volume II - The design and analysis of cohort studies. IARC Sci. Publ.1-406.
Bulpitt EA, Baynesc C, Dunning AM, Evans PR, et al. (2004). Investigation of interleukin-10 and vascular endothelial growth factor single nucleotide polymorphisms in predisposition to breast cancer. Genes Immun. 5: S1-S53.
Cacev T, Radosevic S, Krizanac S and Kapitanovic S (2008). Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 29: 1572-1580.
http://dx.doi.org/10.1093/carcin/bgn164
PMid:18628251
Chan AT, Ogino S and Fuchs CS (2007). Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356: 2131-2142.
http://dx.doi.org/10.1056/NEJMoa067208
PMid:17522398
Cozar JM, Romero JM, Aptsiauri N, Vazquez F, et al. (2007). High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum. Immunol. 68: 698-704.
http://dx.doi.org/10.1016/j.humimm.2007.05.002
PMid:17678726
Crawley E, Kay R, Sillibourne J, Patel P, et al. (1999). Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 42: 1101-1108.
http://dx.doi.org/10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y
Crivello A, Giacalone A, Vaglica M, Scola L, et al. (2006). Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann. N. Y. Acad. Sci. 1089: 98-103.
http://dx.doi.org/10.1196/annals.1386.002
PMid:17261758
Crohn BB and Rosenberg H (1925). The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am. J. Med. Sci. 170: 220-228.
http://dx.doi.org/10.1097/00000441-192508010-00006
De Vita F, Orditura M, Galizia G, Romano C, et al. (1999). Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 86: 1936-1943.
http://dx.doi.org/10.1002/(SICI)1097-0142(19991115)86:10<1936::AID-CNCR9>3.0.CO;2-9
Eskdale J, Kube D, Tesch H and Gallagher G (1997). Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics 46: 120-128.
http://dx.doi.org/10.1007/s002510050250
PMid:9162098
Eskdale J, Gallagher G, Verweij CL, Keijsers V, et al. (1998). Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc. Natl. Acad. Sci. U. S. A. 95: 9465-9470.
http://dx.doi.org/10.1073/pnas.95.16.9465
PMid:9689103 PMCid:21361
Gunter MJ, Canzian F, Landi S, Chanock SJ, et al. (2006). Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol. Biomarkers Prev. 15: 1126-1131.
http://dx.doi.org/10.1158/1055-9965.EPI-06-0042
PMid:16775170
Hanada T and Yoshimura A (2002). Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 13: 413-421.
http://dx.doi.org/10.1016/S1359-6101(02)00026-6
Howell WM and Rose-Zerilli MJ (2007). Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J. Nutr. 137: 194S-199S.
PMid:17182825
Lakatos PL and Lakatos L (2008). Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J. Gastroenterol. 14: 3937-3947.
http://dx.doi.org/10.3748/wjg.14.3937
PMid:18609676 PMCid:2725331
Lee YS, Choi HB, Lee IK, Kim TG, et al. (2010). Association between interleukin-4R and TGF-beta1 gene polymorphisms and the risk of colorectal cancer in a Korean population. Colorectal Dis. 12: 1208-1212.
http://dx.doi.org/10.1111/j.1463-1318.2009.02080.x
PMid:19863607
Macarthur M, Sharp L, Hold GL, Little J, et al. (2005). The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol. Biomarkers Prev. 14: 1613-1618.
http://dx.doi.org/10.1158/1055-9965.EPI-04-0878
PMid:16030091
Midgette AS, Wong JB, Beshansky JR, Porath A, et al. (1994). Cost - Effectiueness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med. Decis. Making 14: 108-117.
http://dx.doi.org/10.1177/0272989X9401400203
PMid:8028463
Shin HD, Park BL, Kim LH, Jung JH, et al. (2003). Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum. Mol. Genet. 12: 901-906.
http://dx.doi.org/10.1093/hmg/ddg104
PMid:12668613
Siegel R, Naishadham D and Jemal A (2012). Cancer statistics, 2012. CA Cancer J. Clin. 62: 10-29.
http://dx.doi.org/10.3322/caac.20138
PMid:22237781
Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, et al. (2001). Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 22: 665-671.
http://dx.doi.org/10.1093/carcin/22.4.665
PMid:11285204
Talseth BA, Meldrum C, Suchy J, Kurzawski G, et al. (2007). Lack of association between genetic polymorphisms in cytokine genes and disease expression in patients with hereditary non-polyposis colorectal cancer. Scand. J. Gastroenterol. 42: 628-632.
http://dx.doi.org/10.1080/00365520601106699
PMid:17454884
Triantafillidis JK, Nasioulas G and Kosmidis PA (2009). Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 29: 2727-2737.
PMid:19596953
Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, et al. (2009). Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control. 20: 1739-1751.
http://dx.doi.org/10.1007/s10552-009-9427-7
PMid:19760027
Tuynman JB, Peppelenbosch MP and Richel DJ (2004). COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit. Rev. Oncol. Hematol. 52: 81-101.
PMid:15501074
Vidal-Vanaclocha F (2009). Inflammation in the molecular pathogenesis of cancer and atherosclerosis. Reumatol. Clin. 5S1: 40-43.
Vogel U, Christensen J, Dybdahl M, Friis S, et al. (2007). Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat. Res. 624: 88-100.
http://dx.doi.org/10.1016/j.mrfmmm.2007.04.006
PMid:17544013
Wilkening S, Tavelin B, Canzian F, Enquist K, et al. (2008). Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 29: 1202-1206.
http://dx.doi.org/10.1093/carcin/bgn101
PMid:18448485
Xie J and Itzkowitz SH (2008). Cancer in inflammatory bowel disease. World J. Gastroenterol. 14: 378-389.
http://dx.doi.org/10.3748/wjg.14.378
PMid:18200660 PMCid:2679126
Zheng C, Huang D, Liu L, Wu R, et al. (2001). Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int. J. Cancer 95: 184-188.
http://dx.doi.org/10.1002/1097-0215(20010520)95:3<184::AID-IJC1031>3.0.CO;2-V